AbbVie Autoimmune Acquisition Strengthens Immunology Portfolio

AbbVie's acquisition of a portfolio of autoimmune diseases from Allergan is a significant move in the world of immunology. This deal brings AbbVie a new range of treatments for patients with autoimmune disorders.

The acquisition includes a portfolio of treatments for conditions such as rheumatoid arthritis, psoriasis, and ulcerative colitis. These conditions affect millions of people worldwide.

AbbVie's immunology portfolio is now stronger than ever, thanks to this acquisition. The company is well-positioned to make a significant impact in the treatment of autoimmune diseases.

See what others are reading: Autoimmune Disease

AbbVie is expanding its immunology pipeline with a $250 million deal to acquire Celsius Therapeutics. This is the third addition to its pipeline in the last four months.

AbbVie is paying $250 million to acquire Celsius Therapeutics, which is developing an antibody for inflammatory bowel disease. This is part of a series of deals to shore up its pipeline of inflammatory drugs.

Here's an interesting read: 250 Грн В Долларах

Celsius has completed a Phase 1 study for its lead program, CEL383, which inhibits a protein coding gene called TREM1. This gene intensifies an inflammatory response that leads to the development of IBD.

AbbVie is eager to advance the development of CEL383, with a goal of helping more patients with IBD achieve remission. This is according to Kori Wallace, AbbVie's global head of immunology clinical development.

Immunology drugmakers have been in the spotlight lately, drawing investor interest in both the private and public markets. AbbVie is one of several major pharma companies to buy an immune drugmaker recently.

Takeda has also been active in the market, licensing a psoriasis treatment from Nimbus Therapeutics for $4 billion. Roche made a $7.1 billion deal to buy a Roivant subsidiary, and startups like Mirador Therapeutics have drawn hundreds of millions of dollars in private investment.

Celsius had previously inked an agreement with Johnson & Johnson to find predictive biomarkers in a clinical trial of patients with ulcerative colitis. This is just one example of the partnerships being formed in the industry.

See what others are reading: Celsius Holdings Earnings